2022
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
Abstract: Background: The novel and highly effective CFTR modulator combination of elexacaftor-tezacaftor-ivacaftor (ETI) has been shown to improve lung function and body weight in people with Cystic Fibrosis (pwCF) carrying a F508del mutation. However, the impact of these modulators on gastrointestinal (GI) symptoms is relatively unknown. Therefore, the CFAbd-Score was developed and validated following FDA recommendations for development of a PROM including focus groups, multidisciplinary CF specialists, people with CF…
Search citation statements
Paper Sections
Select...
65
24
12
4
Citation Types
8
93
5
1
Year Published
Range
2022
2026
Publication Types
Select...
68
12
6
2
Relationship
10
78
Authors
Journals
Cited by 88 publications
(107 citation statements)
References 40 publications
8
93
5
1
Smart CitationsHow the paper below cites the one you are viewing
“…Our data did not show important variations in BMI in children after 24 weeks of treatment with ETI. This result contrast with other studies conducted both in children >12 years and adults, 31,33 showing that ETI promotes weight gain and BMI increase. It also contrasts with an open‐label study involving 66 children aged 6–11 years, which reported a mean increase in BMI SDS of 0.37 after 24 weeks of ETI treatment 19 .…”
Section: Discussion
contrasting
confidence: 99%
Abstract